Piper Sandler keeps Buy rating for AbbVie stock at USD 303.00 target

Published on 10/27/2026 at 17:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 16.99 billion in the second quarter, up 10.20 percent year over year. AbbVie stock costs EUR 257.05 on October 27, 2026.

Analyst target and earnings

Piper Sandler maintained a Buy rating and set a USD 303.00 target on October 26, 2026.
Second-quarter revenue reached USD 16.99 billion, up 10.20 percent from the prior year.
AbbVie stock was trading at EUR 257.05 at Lang & Schwarz on October 27, 2026 at 5:01 p.m. CEST.
AbbVie had a market capitalization of USD 506.6 billion as of October 27, 2026.

AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) is trading at EUR 257.05 at Lang & Schwarz on October 27, 2026 at 5:01 p.m. CEST. Piper Sandler analyst David Amsellem maintained a Buy rating and set a USD 303.00 price target on October 26, 2026, according to Markets Insider.

Revenue gives the target context

AbbVie reported USD 16.99 billion in revenue for the second quarter of 2026, compared with USD 15.42 billion in the second quarter of 2025. Net profit reached USD 3.61 billion, versus USD 938.00 million a year earlier, according to Markets Insider.

52-week range remains wide

AbbVie was trading at USD 286.68 on the NYSE at 12:04 p.m. ET on October 27, 2026. Its 52-week range was USD 190.75 to USD 291.40, while volume stood at 789,221 shares in the same session. The euro quotation therefore sits below the reported home-market high, but the currencies are not combined.

Valuation and upcoming dates

AbbVie had a market capitalization of USD 506.6 billion and a price-to-earnings ratio of 80.72 as of October 27, 2026. MarketBeat reported on October 24, 2026 that 30 analysts carried a Moderate Buy consensus, with an average target of USD 279.86, according to MarketBeat. The same report said the next quarterly dividend of USD 1.73 per share was scheduled for November 16, 2026.

Comparison with peers

AbbVie: price-to-earnings ratio 80.72, market capitalization USD 506.6 billion, volume 789,221 shares on October 27, 2026.
Johnson & Johnson (NYSE, USD): daily change 0.58 percent, price-to-earnings ratio 40.60, market capitalization USD 644.8 billion on October 27, 2026.
Bristol-Myers Squibb (NYSE, USD): daily change minus 0.28 percent, price-to-earnings ratio 13.53, market capitalization USD 125.5 billion on October 27, 2026.

Investor view stays tied to execution

The central question is whether revenue growth can support AbbVie's valuation while upcoming results test expectations. Piper Sandler's USD 303.00 target is above the latest NYSE quote, while MarketBeat's broader average target is lower, showing a wide spread in current analyst assumptions.

At Lang & Schwarz, AbbVie stock was trading at EUR 257.05 on October 27, 2026 at 5:01 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.